Review decisions made by topic
| Topic/individual measures implemented (number of reviews) | Number of times the following decisions were made at point of review | ||
|---|---|---|---|
| Change medication | Further investigation | No action | |
| 1 NSAIDS and antiplatelets (n=290) | 101 (35%) | 97 (33%) | 92 (32%) |
| 1.1 High-risk use in patients with GI risk factors (n=120)*,† | 54 (45%) | 21 (18%) | 45 (38%) |
| 1.2 High-risk use of NSAIDs in patients with renal risk factors (n=161)‡ | 44 (27%) | 72 (45%) | 45 (28%) |
| 1.3 High-risk use of NSAIDs in heart failure (n=9) | 3 (33%) | 4 (44%) | 2 (22%) |
| 2. Asthma (n=148) | 10 (7%) | 26 (18%) | 112 (76%) |
| 2.1 Underuse of inhaled corticosteroids (n=130)§ | 7 (5%) | 23 (18%) | 100 (77%) |
| 2.2 High-risk use of β-blockers (n=18)¶ | 3 (17%) | 3 (17%) | 12 (67%) |
| 3. Atrial fibrillation (n=201) | 3 (1%) | 34 (17%) | 164 (82%) |
| 3.1 Underuse/low intensity of thromboembolic prophylaxis (n=178) | 1 (1%) | 34 (19%) | 143 (80%) |
| 3.2 High-risk use of oral anticoagulants (n=23) | 2 (9%) | 0 (0%) | 21 (91%) |
The data reported on topics 1 (NSAID and antiplatelet) and 2 (asthma) measures are from all four practices and the topic 3 (atrial fibrillation) data are from three of the pilot practices.
*NSAID prescription (in previous 12 weeks) without GI protection to people with at least one of the following risk factors: (i) history of peptic ulcer, (ii) aged ≥75, (iii) aged ≥65 and on aspirin, (iv) aged ≥65 and on warfarin.
†Aspirin prescription (in previous 12 weeks) without GI protection to people with at least one of the following risk factors: (i) history of peptic ulcer, (ii) aged ≥65 and on clopidogrel, (iii) aged ≥65 and on warfarin.
‡NSAID prescription to people with at least one of the following risk factors: (i) CKD stages 3–5, (ii) on ACEI/ARB, (iii) on diuretic, (iv) on combination of ACEI/ARB and diuretic.
§No prescription of inhaled corticosteroid (in previous 12 weeks) in patient with asthma and at least one of the following risk factors: (i) prescription for three or more SABA inhalers in previous 12 weeks, (ii) prescription of LABAs, leukotriene receptor antagonist, theophylline or oral prednisolone in previous 12 weeks.
¶Prescription of any β-blocker if ‘active asthma’ (prescription of a SABA inhaler in previous 48 weeks) or prescription of a non-cardioselective β-blocker if ‘previous asthma’ (no prescription of a SABA inhaler in the previous 48 weeks).
ACEI/ARB, ACE inhibitors/angiotensin receptor blocker; CKD, chronic kidney disease; GI, gastrointestinal; LABAs, long-acting β2-agonists; NSAIDs, non-steroidal anti-inflammatory drugs; SABA, short acting β agonists.